Navigation Links
Schering-Plough Reports Financial Results for 2009 Second Quarter
Date:7/21/2009

e and 7 percent unfavorable foreign exchange impact) compared to sales of $111 million in the second quarter of 2008.

Animal Health sales totaled $677 million in the 2009 second quarter, a 17 percent decrease as compared to $818 million in the second quarter of 2008 (7 percent operational decrease and 10 percent unfavorable foreign exchange impact). The sales decline was a result of the overall economic environment, difficult comparisons against the 2008 launch of bluetongue vaccine and the impact of 2008 product divestitures.

Consumer Health Care sales were $381 million in the 2009 second quarter, down 5 percent versus the 2008 period. The decrease was primarily due to lower sales of sun care products, which primarily reflected the impact of unseasonable weather conditions in many parts of the U.S. Higher sales of MIRALAX helped offset lower sales of OTC CLARITIN.

Schering-Plough does not record sales of its cholesterol joint venture and incurs substantial costs such as selling, general and administrative costs that are not reflected in "Equity income" and are borne by the overall cost structure of Schering-Plough. As a result, Schering-Plough's gross margin and ratios of selling, general and administrative (SG&A) expenses and R&D expenses as a percentage of sales do not reflect the benefit of the impact of the cholesterol joint venture's operating results.

Schering-Plough's gross margin on a GAAP basis was unfavorably affected by purchase accounting adjustments and totaled 65.1 percent for the 2009 second quarter as compared to 61.2 percent in the 2008 period. On a reconciled basis, the gross margin percentage decreased to 68.1 percent for the second quarter of 2009 as compared to 68.4 percent for the second quarter of 2008, primarily due to the unfavorable impact from foreign exchange.

SG&A expenses were $1.6 billion in the second qua
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27

Related biology technology :

1. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
2. Schering-Plough Announces Pricing of Senior Notes Offering
3. Schering-Plough to Webcast Presentation at Merrill Lynch Global Pharmaceutical, Biotech & Medtech Conference
4. Schering-Plough Receives Approval from European Commission for Planned Acquisition of Organon BioSciences N.V.
5. Schering-Plough Completes Acquisition of Organon BioSciences
6. Schering-Plough Wins Three of Scrips Top Pharma Industry Awards
7. Schering-Plough Schedules Conference Call and Webcast for 2007 Fourth Quarter, Full-Year Financial Result
8. Schering-Plough to Webcast Presentation at Morgan Stanley Pharmaceutical CEOs Unplugged Conference
9. Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA
10. Schering-Plough Announces Sugammadex New Drug Application Filed in Japan
11. FDA Grants Priority Review for Schering-Ploughs Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/3/2009)PHILADELPHIA, Dec. 3 Shire plc (LSE: SHP, Nasdaq: SHPGY ), the global specialty biopharmaceutical company, today announced a voluntary recall of five lots and voluntary market withdrawal of one lot
(Date:12/3/2009)NEW DELHI, India, Dec. 3 /PRNewswire-Asia/ -- Dr. Susan Jiang, M.D., Ph.D.,Chief Science Officer at Shenzhen Beike Biotechnology Co. Ltd.,( http://www.beikebiotech.com ), spoke at a conference on Hig
(Date:12/2/2009)NEW YORK, Dec. 2 Reportlinker.com announces that a new market research report is available in its catalogue: ,, Carbondioxide Incubators - A Global Market Perspective ,, http://www.reportlinker.co
(Date:12/2/2009)TUSTIN, Calif., Dec. 2 Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM ) today reported completion of patient enrollment in a dose confirmation and dosimetry trial of Cotara® in patients with rel
Breaking Biology Technology:Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 2Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 3Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 4Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 5Beike Biotechnology CSO Speaks on Role of Stem Cells in Treating Diabetic Foot Disease at IPA Diabetic Foot Care Conference, India 2Beike Biotechnology CSO Speaks on Role of Stem Cells in Treating Diabetic Foot Disease at IPA Diabetic Foot Care Conference, India 3Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective 2Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective 3Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective 4Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 2Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 3Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 4Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 5
...CET, AMSTERDAM, February 20 Amsterdam Molecular,...d of human gene therapy,today reported its full ye..., raising gross proceeds of EUR 55.7 million - Ca...30, 2007 - U.S. FDA orphan drug designation for l.../II in LPL type I deficiency - Pre-registration t...
...emonstrated by a collaboration between researchers...logy (NIST), Penn State and the University of Kent...duce large arrays of organic electronic transistor...ns including flexible displays, intelligent paper ...diagnostics. , In a paper posted this week,* the ...
...ion,(Nasdaq: KNSY ) is scheduled to present at th... at the Mission Bay Conference Center in San,Franc..., Kensey Nash,s Chief Operating Officer, will deli...ately at 2:50 p.m. (PT). The,presentation material...p://www.kenseynash.com ) beginning at 2:50 p.m. (P...
Other Biology Technology:Amsterdam Molecular Therapeutics Reports Full Year Results 2007 2Amsterdam Molecular Therapeutics Reports Full Year Results 2007 3Amsterdam Molecular Therapeutics Reports Full Year Results 2007 4Amsterdam Molecular Therapeutics Reports Full Year Results 2007 5Amsterdam Molecular Therapeutics Reports Full Year Results 2007 6Amsterdam Molecular Therapeutics Reports Full Year Results 2007 7Directed self-ordering of organic molecules for electronic devices 2
(Date:12/3/2009)Grand Rapids, Mich. (Dec. 3, 2009) Van Andel Research Institute (VARI) researchers have determined precisely how the plant hormone abscisic acid (ABA) works at the molecular level to help plants re
(Date:12/3/2009)Forest dwellers must be included in the design of the upcoming forest deal at Copenhagen in order to avoid a humanitarian crisis, according to a scientist at the University of Leeds. , Writing today
(Date:12/3/2009)UPTON, NY A team of scientists from the U.S. Department of Energy,s (DOE) Brookhaven National Laboratory, Harvard University, and the Indian Institute of Science has made a major step in understandin
Breaking Biology News(10 mins):VAI researchers find long awaited key to creating drought resistant crops 2VAI researchers find long awaited key to creating drought resistant crops 3Forest deal at Copenhagen must avoid creating 'carbon refugees' 2Grooving down the helix 2Grooving down the helix 3Vion Pharmaceuticals Engages Merriman Curhan Ford to Evaluate Strategic Alternatives 5403 1Vion Pharmaceuticals Engages Merriman Curhan Ford to Evaluate Strategic Alternatives 5403 2Vion Pharmaceuticals Engages Merriman Curhan Ford to Evaluate Strategic Alternatives 5403 3News brief 3A Effects of aspirin and folic acid on inflammation markers for colorectal adenomas 59312 1Drop in Certain Visual Skills May Precede Alzheimers 59310 1Drop in Certain Visual Skills May Precede Alzheimers 59310 2
...pression of genes may be the reason why people who...ckly develop a tolerance, biologists at The Univer...eam, led by graduate student Yan Wang, used the fr...to determine how the nervous system becomes tolera...The team,s work appears in the October 16 issue of...
...ore acid, with potentially devastating consequence...eefs and provide much of the Earths breathable oxy...up of carbon dioxide (CO 2 ) in the atmosphere, di... be lethal for animals with chalky skeletons which...ife. , Acid oceans will be among the issues explo...
...DED BROKERAGE TO UTILIZE TITANIUM,S ... Oct. 16 Titanium Group, Ltd,(OTC Bulletin Board:...s,provider announced today that it has signed a co...) (SHA: 600837). Titanium will install its,Biometr...ated office in,Hong Kong. Haitong, listed in the S...
Other Biology News:Tolerance to inhalants may be caused by changes in gene expression 2Acid oceans warning 2Titanium Group Announces Contract With Haitong Securities 2Titanium Group Announces Contract With Haitong Securities 3Titanium Group Announces Contract With Haitong Securities 4
Mouse Anti-Human ACP2 Monoclonal Antibody, Unconjugated, Clone M1-4A12 from Novus Biologicals
Mouse Anti-Human DCAMKL2 Monoclonal Antibody, Unconjugated, Clone 2A5 from Novus Biologicals
...ew IKATUBE ULTRA TURRAX Tube Disperser System from... system. It offers a cleaner, safer, and more effi...processes sample volumes from 2 to 15 ml inside se...chers can choose one of 4 different tube types. Ea...
...ewest member of Wyatt Technology's family of light...our high temperature chromatograph and enables you...rmoplastic polymers. The HTmD is easily installed ... 2000 device and enables you to get three angles o...
Biology Products: